ELAVL1

2 papers6 findings

HGNC 3312 NCBI Gene 1994 Taxon 9606

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

A gene’s or a process’s line counts the gene with the processes named after it, as NLRP3 with the NLRP3 inflammasome, and the trials of drugs aimed at it.

2 independent labs in 2 countries

Humans1
Animals1

Effects

Inflammation

upin human cells1

1 study

ELAVL1 induces inflammation in human cells.
“HuR overexpression alone induced a pro-inflammatory phenotype via stabilization of its mRNA targetome.”
Cellsvascular endothelium
The RNA-binding protein HuR controls atherosclerotic disease progression of carotid and femoral arteries
AHA Scientific Sessions 2025 abstract3 Nov 2025

Associations

Major adverse cardiovascular events

upin humans1

1 study

ELAVL1 is associated with major adverse cardiovascular events in humans.
“High HuR levels also correlated with greater MACE incidence over a median 48-month follow-up (log-rank P=0.009).”
Humans48 months
The RNA-binding protein HuR controls atherosclerotic disease progression of carotid and femoral arteries
AHA Scientific Sessions 2025 abstract3 Nov 2025

Atherosclerosis

upin humans1

1 study

ELAVL1 predicts atherosclerosis in humans.
“baseline HuR levels predicted accelerated subclinical atherosclerosis progression, reflected by increased carotid and femoral plaque number”
Humans
The RNA-binding protein HuR controls atherosclerotic disease progression of carotid and femoral arteries
AHA Scientific Sessions 2025 abstract3 Nov 2025